Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial
EuroIntervention 2014;10:58-64 published online ahead of print April 2014. DOI: 10.4244/EIJV10I1A11
Sune Haahr Pedersen1*, MD, PhD; Matthias Pfisterer2, MD; Christoph Kaiser2, MD, DmSc; Jan Skov Jensen1, MD, PhD, DmSc; Hannes Alber3, MD; Peter Rickenbacher4, MD; Rikke Sørensen1, MD, PhD; Allan Iversen1, MD, PhD; Magnus Thorsten Jensen1, MD; Kim Wadt1, MD; Søren Galatius1, MD, DmSc; for the BASKET-PROVE Investigators
1. Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark; 2. Department of Cardiology, University Hospital, Basel, Switzerland; 3. Department of Cardiology, University Hospital, Innsbruck, Austria; 4. Department of Cardiology, Univ
Aims: The use of drug-eluting stents (DES) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is controversial and not yet endorsed in clinical guidelines.